BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38723244)

  • 1.
    Zang Z; Yin Y; Liu C; Zhu Q; Huang X; Li H; Yang R
    Epigenetics; 2024 Dec; 19(1):2352683. PubMed ID: 38723244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA.
    Tang Q; Holland-Letz T; Slynko A; Cuk K; Marme F; Schott S; Heil J; Qu B; Golatta M; Bewerunge-Hudler M; Sutter C; Surowy H; Wappenschmidt B; Schmutzler R; Hoth M; Bugert P; Bartram CR; Sohn C; Schneeweiss A; Yang R; Burwinkel B
    Oncotarget; 2016 Sep; 7(39):64191-64202. PubMed ID: 27577081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
    Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
    Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
    Huang R; Ding P; Yang F
    Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RPTOR methylation in the peripheral blood and breast cancer in the Chinese population.
    Yin Y; Lei S; Li L; Yang X; Yin Q; Xu T; Zhou W; Li H; Gu W; Ma F; Yang R; Zhang Z
    Genes Genomics; 2022 Apr; 44(4):435-443. PubMed ID: 34767153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation array analyses identified breast cancer-associated HYAL2 methylation in peripheral blood.
    Yang R; Pfütze K; Zucknick M; Sutter C; Wappenschmidt B; Marme F; Qu B; Cuk K; Engel C; Schott S; Schneeweiss A; Brenner H; Claus R; Plass C; Bugert P; Hoth M; Sohn C; Schmutzler R; Bartram CR; Burwinkel B
    Int J Cancer; 2015 Apr; 136(8):1845-55. PubMed ID: 25213452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Cell Free Nuclear DNA, Mitochondrial DNA and Global DNA Methylation: Potential Noninvasive Biomarkers for Breast Cancer Diagnosis.
    Pasha HA; Rezk NA; Riad MA
    Cancer Invest; 2019; 37(9):432-439. PubMed ID: 31516038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterisation of cell line models for triple-negative breast cancers.
    Grigoriadis A; Mackay A; Noel E; Wu PJ; Natrajan R; Frankum J; Reis-Filho JS; Tutt A
    BMC Genomics; 2012 Nov; 13():619. PubMed ID: 23151021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detailed DNA methylation characterisation of phyllodes tumours identifies a signature of malignancy and distinguishes phyllodes from metaplastic breast carcinoma.
    Meyer B; Stirzaker C; Ramkomuth S; Harvey K; Chan B; Lee CS; Karim R; Deng N; Avery-Kiejda KA; Scott RJ; Lakhani S; Fox S; Robbins E; Shin JS; Beith J; Gill A; Sioson L; Chan C; Krishnaswamy M; Cooper C; Warrier S; Mak C; Rasko JE; Bailey CG; Swarbrick A; Clark SJ; O'Toole S; Pidsley R
    J Pathol; 2024 Apr; 262(4):480-494. PubMed ID: 38300122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A seven-DNA methylation signature as a novel prognostic biomarker in breast cancer.
    Tao C; Luo R; Song J; Zhang W; Ran L
    J Cell Biochem; 2020 Mar; 121(3):2385-2393. PubMed ID: 31646666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood-based DNA methylation as biomarker for breast cancer: a systematic review.
    Tang Q; Cheng J; Cao X; Surowy H; Burwinkel B
    Clin Epigenetics; 2016; 8():115. PubMed ID: 27895805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Peripheral blood
    Zhou X; Lei S; Li L; Xu T; Gu W; Ma F; Yang R
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Oct; 41(10):1456-1463. PubMed ID: 34755660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between
    Li J; Zhou X; Li L; Ji L; Li J; Qu Y; Wang Z; Zhao Y; Zhang J; Liang F; Liu J; Gu W; Yang R; Ma F; Dai L
    Front Oncol; 2023; 13():1148635. PubMed ID: 37274256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Intrinsic Breast Cancer Subtypes: The Clinical Utility of Epigenetic Biomarkers and
    Sadzeviciene I; Snipaitiene K; Scesnaite-Jerdiakova A; Daniunaite K; Sabaliauskaite R; Laurinaviciene A; Drobniene M; Ostapenko V; Jarmalaite S
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of 14-3-3 sigma (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis.
    Ye M; Huang T; Ying Y; Li J; Yang P; Ni C; Zhou C; Chen S
    Oncotarget; 2017 Feb; 8(6):9230-9242. PubMed ID: 27999208
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Li J; Yin Y; Huang H; Li M; Li H; Zhang M; Jiang C; Yang R
    Epigenomics; 2023 Dec; 15(23):1257-1272. PubMed ID: 38126720
    [No Abstract]   [Full Text] [Related]  

  • 17. DNA methylation patterns of RAR-β2 and RASSF1A gene promoters in FNAB samples from Greek population with benign or malignant breast lesions.
    Kougioumtsidou N; Vavoulidis E; Nasioutziki M; Symeonidou M; Pratilas GC; Mareti E; Petousis S; Chatzikyriakidou A; Grimbizis G; Theodoridis T; Miliaras D; Dinas K; Zepiridis L
    Diagn Cytopathol; 2021 Jan; 49(1):153-164. PubMed ID: 32530576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer.
    Park SY; Seo AN; Jung HY; Gwak JM; Jung N; Cho NY; Kang GH
    PLoS One; 2014; 9(6):e100429. PubMed ID: 24971511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
    Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high-level immune infiltration status.
    Li HN; Li XR; Lv ZT; Cai MM; Wang G; Yang ZF
    Cancer Med; 2020 Dec; 9(24):9554-9570. PubMed ID: 33058542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.